Bad cholesterol has just become worse. Known to cause heart disease and hardening of the arteries, it has now been linked with a cell pathway that promotes cancer.
Researchers at the University of Illinois in Chicago have described a new role for cholesterol in the activation of a cellular signalling pathway that has been associated with cancer.
"Our research points to a new regulatory role for cholesterol. It also presents an exciting new therapeutic target for suppressing a key cell signalling pathway to treat or prevent cancer," explained principal investigator Wonhwa Cho, a professor of chemistry at University of Illinois.
Cells employ thousands of signalling pathways to conduct their functions.
"Canonical Wnt" signalling is a pathway that promotes cell growth and division and is most active in embryonic cells during development.
Overactivity of this signalling pathway in mature cells is thought to be a major driver in the development of cancer.
Cho and his colleagues discovered a binding site for cholesterol on a protein called "Dishevelled".
"Dishevelled" is involved in "canonical Wnt" signalling that plays a role in processes like cell movement and organisation.
The researchers found that when cholesterol is bound to "Dishevelled", the signal continues along the canonical Wnt signalling pathway.
Without cholesterol, the signalling cannot occur.
"Our research provides a mechanism for how cholesterol promotes pathways that lead to cancer," Cho noted.
"A drug that interferes with the binding of cholesterol to Dishevelled," Cho said, "may be effective against cancers that are driven by canonical Wnt signalling."
Such cancers include colon cancer, melanoma, breast cancer and lung cancer.
The findings were reported in the journal Nature Communications.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
